Pressure BioSciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Summary of Customer Concentration Risk Percentage

The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2016 and 2015.

	For the Three Months Ended
	June 30,
	2016			2015
Top Five Customers		68	%		65	%
Federal Agencies		8	%		27	%

	For the Six Months Ended
	June 30,
	2016			2015
Top Five Customers		40	%		49	%
Federal Agencies		10	%		22	%

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2016 and December 31, 2015:

	June 30, 2016			December, 31, 2015
Top Five Customers		73	%		93	%
Federal Agencies		0	%		1	%

Schedule of Inventories

The composition of inventory is as follows:

	June 30, 2016			December 31, 2015
Raw materials	$	407,949		$	310,367
Finished goods		644,433			778,004
Inventory Reserve		(50,000	)		(50,000	)
Total	$	1,002,382		$	1,038,371

Summary of Computation of Loss per Share

The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2016 and 2015:

	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2016			2015			2016			2015
Numerator:
Net loss	$	961,829		$	(1,386,241	)	$	(4,988,561	)	$	(2,772,232	)
Accretion of interest and amortization of debt discount		991,286			-			-			-
Change in fair value of derivative liabilities		(2,016,593	)		-			-			-
Preferred dividends accrued		-			(6,811	)		-			(23,479	)
Net loss applicable to common shareholders	$	(763,478	)	$	(1,393,052	)	$	(4,988,561	)	$	(2,795,711	)

Denominator for basic and diluted loss per share:
Weighted average common stock shares outstanding		25,953,828			19,682,632			24,481,039			19,247,895

Net effect of dilutive common stock equivalents		44,808,781			-			-			-

Weighted average shares outstanding - diluted		70,762,609			19,682,632			24,481,039			19,247,895

Income (loss) per common share - basic	$	0.04		$	(0.07	)	$	(0.20	)	$	(0.14	)

Income (loss) per common share - diluted	$	(0.00	)	$	(0.07	)	$	(0.20	)	$	(0.14	)

Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share

	As of June 30,
	2016		2015
Stock options		5,385,250		3,251,250
Convertible debt		25,343,864		14,420,144
Common stock warrants		26,403,340		19,182,201
Convertible preferred stock:
Series D Convertible Preferred Stock		750,000		750,000
Series G Convertible Preferred Stock		865,700		865,700
Series H Convertible Preferred Stock		1,000,000		1,000,000
Series H2 Convertible Preferred Stock		2,100,000		2,100,000
Series J Convertible Preferred Stock		3,546,000		3,546,000
Series K Convertible Preferred Stock		6,816,000		11,416,000
		72,210,153		56,531,295

Summary of Stock Based Compensation Expense

	For the Three Months Ended June 30,
	2016		2015
Research and development		15,650		11,523
Selling and marketing		9,803		7,099
General and administrative		65,396		36,994
Total stock-based compensation expense		90,849		55,616

	For the Six Months Ended June 30
	2016		2015
Research and development		36,031		22,865
Selling and marketing		22,493		14,075
General and administrative		133,787		73,566
Total stock-based compensation expense		192,311		110,506

Schedule of Liabilities Measured at Fair Value on Recurring Basis

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2016:

			Fair value measurements at June 30, 2016 using:
	June 30, 2016		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Available-For-Sale Equity Securities		81,783		81,783		0		0
Total Financial Assets	$	81,783	$	81,783	$	-	$	0

	June 30, 2016		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Series D Preferred Stock Purchase Warrants	$	167,702		-		-	$	167,702
Warrants Issued with Convertible Debt		4,385,293		-		-		4,385,293
Conversion Option Derivative Liabilities		5,023,449		-		-		5,023,449
Total Derivatives	$	9,576,444	$	-	$	-	$	9,576,444

The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs for the six months ended June 30, 2016:

	December 31, 2015		Issuance fair value		Change in fair value			Gain on extinguishment of derivative liabilities		June 30, 2016
Available-For-Sale Equity Securities	$	294,522			$	(212,739	)	$	-	$	81,783
Total Financial Assets	$	294,522	$	-	$	(212,739	)	$	-	$	81,783

	December 31, 2015		Issuance fair value		Change in fair value			June 30, 2016
Series D Preferred Stock Purchase Warrants	$	173,526	$	-	$	(5,824	)	$	167,702
Convertible Debt Warrants		3,122,450		1,094,432		168,411			4,385,293
Conversion Option Liabilities		3,940,791		1,547,127		(464,469	)		5,023,449
Total Derivatives	$	7,236,767	$	2,641,559	$	(301,882	)	$	9,576,444

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015:

			Fair value measurements at December 31, 2015 using:
	December 31, 2015		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Available-For-Sale Equity Securities		294,522		294,522		-		-
Total Financial Assets	$	294,522	$	294,522	$	-	$	-

	December 31, 2015		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Series D Preferred Stock Purchase Warrants	$	173,526		-		-	$	173,526
Warrants Issued with Convertible Debt		3,122,450		-		-		3,122,450
Conversion Option Derivative Liabilities		3,940,791		-		-		3,940,791
Total Derivatives	$	7,236,767	$	-	$	-	$	7,236,767

Schedule of Fair Value Assumptions

The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis.

Assumptions	November 10, 2011			Warrants revalued at December 31, 2015			Warrants revalued at June 30, 2016
Expected life (in months)		60.0			11.0			4.0
Expected volatility		104.5	%		104.9	%		96.2	%
Risk-free interest rate		0.875	%		0.65	%		0.26	%
Exercise price	$	0.81		$	0.25		$	0.25
Fair value per warrant	$	0.54		$	0.16		$	0.16

The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt throughout the period reflected on a per share common stock equivalent basis.

Assumptions	At Issuance Fair value			Warrants revalued at December 31, 2015			Warrants revalued at June 30, 2016
Expected life (in months)		36.0-60.0			55.0-60.0			48.0-60.0
Expected volatility		114.3 - 138.3	%		136.3-141.6	%		137.9 -142.2	%
Risk-free interest rate		0.86-1.69	%		1.29-1.76	%		1.01-1.21	%
Exercise price	$	0.40-0.42			0.40		$	0.40
Fair value per warrant	$	0.19-$.40			0.30		$	0.32-$0.40

The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis.

Assumptions	At Issuance fair value			Conversion options revalued at December 31, 2015			Conversion options revalued at June 30, 2016
Expected life (in months)		3-24			18-24			6-24
Expected volatility		97.6-153.8	%		112.2-114.7	%		94.8-113.67	%
Risk-free interest rate		0.37-0.99	%		1.06	%		0.36-0.73	%
Exercise price	$	0.24-$0.45		$	0.28		$	0.28-$0.45
Fair value per conversion option	$	0.07-$0.30		$	0.14-$0.33		$	0.08-$0.30

- Definition

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details